Vizimpro (dacomitinib)
- Region
- 🇪🇺 EU
- Active substance
- dacomitinib
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Thu 31 Jan 2019
- EU approval
- Tue 02 Apr 2019
- Application
- EMEA/H/C/004779
- ATC
- L01EB07
- Official record
- www.ema.europa.eu
Indication
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
Regulatory milestones
No milestones recorded in the last year.
Follow Vizimpro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.